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Abstract
Acute aflatoxin exposure can cause death and disease (aflatoxicosis) in humans. Aflatoxicosis 
fatality rates have been documented to be as high as 40% in Kenya. The inclusion in the diet of 
calcium silicate 100 (ACCS100), a calcium montmorillonite clay, may reduce aflatoxin 
bioavailability, thus potentially decreasing the risk of aflatoxicosis. We investigated the efficacy, 
acceptability and palatability of ACCS100 in a population in Kenya with recurring aflatoxicosis 
outbreaks. Healthy adult participants were enrolled in this double-blinded, crossover clinical trial 
in 2014. Following informed consent, participants (n = 50) were randomised to receive either 
ACCS100 (3 g day−1) or placebo (3 g day−1) for 7 days. Treatments were switched following a 5-
day washout period. Urine samples were collected daily and assessed for urinary aflatoxin M1 
(AFM1). Blood samples were collected at the beginning and end of the trial and assessed for 
aflatoxin B1-lysine adducts from serum albumin (AFB1-lys). AFM1 concentrations in urine were 
significantly reduced while taking ACCS100 compared with calcium carbonate placebo (β = 0.49, 
95% confidence limit = 0.32–0.75). The 20-day interval included both the placebo and ACCS100 
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treatments as well as a washout period. There were no statistically significant differences in 
reported taste, aftertaste, appearance, colour or texture by treatment. There were no statistically 
significant differences in self-reported adverse events by treatment. Most participants would be 
willing to take ACCS100 (98%) and give it to their children (98%). ACCS100 was effective, 
acceptable and palatable. More work is needed to test ACCS100 among vulnerable populations 
and to determine if it remains effective at the levels of aflatoxin exposure that induce aflatoxicosis.
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Introduction
Aflatoxins are harmful secondary metabolites of the moulds Aspergillus flavus and A. 
parasiticus, and they frequently contaminate agricultural produce such as cereals, oilseeds 
and root crops (Williams et al. 2004; Wild 2010). Acute exposure to aflatoxins can cause 
aflatoxicosis and liver failure (Wild & Gong 2010). Recurring aflatoxicosis outbreaks occur 
in Kenya's Eastern Province, where documented aflatoxicosis fatality rates approach 40% 
(Centers for Disease Control and Prevention (CDC) 2004). In Kenya, the first recorded 
aflatoxicosis outbreak occurred in 1981 (Ngindu et al. 1982). Between 2004 and 2014, 
subsequent outbreaks affected nearly 600 individuals and caused 211 deaths (personal 
communication with the Kenya Ministry of Health).
One possible approach to prevent illness associated with acute aflatoxin exposure is the use 
of a naturally occurring calcium montmorillonite clay. Air-classified calcium silicate 100 
(ACCS100) is a refined calcium montmorillonite clay generally recognised as safe by the 
USFDA. The ACCS100 refining process is a simple fractionation method of the parent clay 
resulting in a product that contains the highest percentage of its particles within the size 
range of 45–100 μm, resulting in less quartz and large particles that might negatively 
influence palatability (Marroquin-Cardona et al. 2011). Importantly, ACCS100 clay can be 
included in the diet to adsorb aflatoxins tightly in the gastrointestinal tract, leading to 
decreased bioavailability.
High-affinity binding of aflatoxins to clay (Grant & Phillips 1998; Phillips et al. 2002), 
reduction of aflatoxin bioavailability, prevention of aflatoxicosis and safety at doses as high 
as 2% clay in the diet have been well-documented in animal studies (Phillips et al. 1988, 
1995, 2002; Harvey et al. 1991, 1993; Mayura et al. 1998; Phillips 1999; Afriyie-Gyawu et 
al. 2005) and human clinical trials in the United States and Ghana (Wang 2008; Wang et al. 
2005; Afriyie-Gyawu, Ankrah et al. 2008; Phillips et al. 2008; Mitchell et al. 2014; Pollock 
et al. 2016). Prior to clinical trials, a 2-week safety study was carried out in 50 US adults 
(Wang et al. 2005). This was followed by a 3-month Phase IIa clinical trial in adults, a 2-
week crossover trial in adults and a 2-week safety study in children that found that the clay 
was safe for human consumption at levels as high as 0.25% in the diet and effective at 
reducing aflatoxin biomarkers in serum and urine. No significant differences in 
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haematology, liver and kidney function, electrolytes or minerals were found between 
placebo and active treatment groups. Furthermore, ACCS100 did not affect blood levels of 
micro- and macro-nutrients, such as vitamins A and E (Afriyie-Gyawu, Wang, et al. 2008).
In previous studies, clay was successfully delivered by capsule, or mixed in the diet. We 
envisaged that clay delivery in water might be more rapid and feasible during an outbreak 
period. Based on these studies, it was hypothesised that delivery of ACCS100 in water could 
be used to reduce biomarkers of aflatoxin exposure in urine and serum samples from 
participants living in high-risk regions of Kenya's Eastern Province. Our specific objectives 
in this study were to determine efficacy, acceptability and palatability of ACCS100 in water, 
using a crossover clinical trial in 50 health individuals.
Factors that can affect efficacy, acceptability and palatability include culture, ethnicity, diet, 
institutional policies, the amount of the contaminant and infrastructure. Because these 
factors can differ between countries and even within a single country, it is necessary to test 
an intervention in the specific at-risk population before implementation plans can be 




The study protocol was approved by the Institutional Review Boards at the Kenya Medical 
Research Institute (KEMRI), Centers for Disease Control and Prevention (CDC), and Texas 
A&M University, bearing protocol IDs 2603, 6535.0 and 2013-0311F, respectively. The 
study's clinicaltrial.gov identifier is NCT02188953. The study started in July 2014 and 
ended in August 2014. A double-blinded, crossover clinical trial was conducted in which 50 
participants were randomly assigned to group I or group II (Figure 1). Group I participants 
consumed 1 g of calcium carbonate placebo three times per day for 7 days. They did not 
consume any test material for 5 days (washout period), and completed the study with 1 g of 
ACCS100 three times per day for the last 7 days. Group II participants followed the same 
schedule, except they began with ACCS100 and finished with placebo. Dose ranged from 3 
packet/40 kg to 3 packet/94.5 kg (Table 1). The dose in the current study has been shown to 
be safe and effective in several human trials. Since the ultimate goal of this mitigation 
strategy is for emergency use during outbreak situations, a single minimal effective dose in 
adults and children, respectively, would be the most field-practical.
Intervention
Texas EnteroSorbents, Inc. provided ACCS100 and placebo as 1-g foil sachets packaged for 
individual use. Participants were instructed to consume one sachet with each of their three 
main meals by diluting the sachet in water provided by the study; thus, participants would 
consume 3 g of ACCS100 or placebo per day during the study arms. The sachets were 
coloured pink or green to designate the content (ACCS100 or placebo respectively). The 
study investigators and participants were both blinded regarding treatment type. Each day 
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during the study each participant was provided a sterile urine cup, three treatment sachets 
and three 500-ml bottles of clean water.
Study population
The study was implemented in Kalimani and Kamboo villages of Kamboo sub-location in 
Makueni county, Eastern Kenya. The region is predominately agricultural and composed of 
subsistence farming, and residents eat primarily a maize-based diet. These villages were 
chosen because they had experienced multiple aflatoxicosis outbreaks in the prior decade.
Sampling and enrolment
Field teams employed convenience sampling and went door to door to recruit participants, 
enrolling one adult per household. Inclusion criteria consisted of the following: (1) age ≥ 18 
years; and (2) consumed maize and/or groundnuts at least four times per week. Once a 
participant was identified, written informed consent was obtained. Consent forms were 
supplied in the local language (Akamba) as well as the national language (Kiswahili). 
Participants could decline to participate in any part of the study and were free to withdraw at 
any point. Upon completion of the study, participants were reimbursed with cooking items 
worth approximately 400 Kenya shillings (US$4).
All study participants were provided with detailed study objectives and procedures. After 
consent was provided, each person's medical history, height and weight were recorded and 
their current health status was assessed through a physical example and onsite urine testing. 
Urine specimens were analysed for protein and glucose levels using Chemistrip®2 GP test 
strips from Roche Diagnostics (Indianapolis, IN, USA). These tests helped to rule out many 
health conditions involving the metabolic system, e.g., diseases of the liver (e.g., hepatitis, 
cirrhosis, etc.), kidney (e.g., nephrotic syndrome, renal failure, etc.) and thyroid gland (e.g., 
hypothyroidism, etc.). Participants who reported a history of thyroid disease, heart disease, 
lung disease, kidney disease, gastrointestinal disease or diabetes, or who had protein or 
glucose levels outside the normal range were informed of their result and excluded from the 
study. Female participants aged 18–49 were assessed for pregnancy status onsite using Sure-
Vue® urine human chorionic gonadotropin strips (Fisher Healthcare, Pittsburgh, PA, USA). 
Participants who were pregnant were excluded because of unknown effects of ACCS100 on 
human pregnancy (although studies on pregnant rats have reported no serious adverse 
effects). Participants not excluded were enrolled in the study and randomly assigned to 
group I or II.
Data collection
An enrolment survey was administered that included questions regarding the duration of 
residency in the village, source of maize and the shelf-life of their maize stock.
Participants provided a first morning void urine sample at baseline, and again for each of the 
7 days of each treatment arm. Given the short half-life of aflatoxin in the urine (1–2 days) 
and the transit time of ACCS100 in the gastrointestinal tract (1–3 days), aflatoxin M1 should 
have completely rebounded during the wash-out period. Urine samples were collected, 
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aliquoted and frozen each morning, then kept frozen until laboratory analysis. Two blood 
samples were also collected from each participant at baseline (day 0) and completion (day 
20) of the trial for AFB1-lys analysis.
Following each treatment arm, a questionnaire was administered that asked participants to 
rate the taste, aftertaste, smell, texture, appearance and colour of the sachet contents they had 
been consuming using a five-point Likert type scale (1 = really bad; 5 = really good).
Study monitors completed a worksheet each day during the study to record participant 
adherence to protocol (i.e., daily use of ACCS100 or placebo), the occurrence of side effects 
and diet. For adherence, daily use of ACCS100 or placebo was obtained by asking 
participants to self-report their consumption, and by collecting empty treatment sachets. For 
side effects, additional information was collected regarding side-effect severity (i.e., mild, 
moderate or severe), time of day the side effect occurred (i.e., a.m., noon or p.m.), and 
whether or not the participant sought treatment.
Acceptance was also assessed by administering a questionnaire at the end of the study to 
collect the participant's perceptions of ACCS100 and whether they would be willing to 
consume ACCS100 in future, or whether they would be willing to have their children 
consume ACCS100.
Determination of urinary AFM1
The exposure of AFM1 in humans is by ingestion of food contaminated with AFB1 which is 
then metabolised to AFM1, or consumption of contaminated milk and dairy products. Urine 
samples were analysed at Texas A&M University. Analysis of urinary AFM1 levels followed 
methods reported by Groopman et al. (1992) with the modifications of Sarr et al. (1995) and 
Wang et al. (1999). Urine samples were centrifuged at 2300 rpm, and 5.0 ml of supernatant 
were collected, acidified with 0.5 ml of 1.0 M ammonium formate (pH 4.5) and diluted with 
water to a total volume of 10.0 ml. Samples were then loaded onto a 3-ml preparative 
Aflatest® WB immunoaffinity column (VICAM, Watertown, MA, USA) at a flow rate of 1 
ml min−1. Following washing of the column, the aflatoxin fraction was eluted from the 
column with 2 ml of 80% methanol, dried under N2 and resuspended in 200 μl of a 1:1 
solution of methanol:20 mM ammonium formate. Samples were analysed using a Waters 
HPLC system (Waters Corporation, Milford, MA, USA) with fluorescence detection 
capabilities. A 250 × 4.6 mm Luna C-18 column with pore size 100 Å and particle size 5 μm 
(Phenomenex, Torrance, CA, USA) was used to resolve AF metabolites. The mobile phase 
consisted of 22% ethanol buffered with 20 mM ammonium formate (pH 3.0) in water. 
Isocratic elution of the mobile phase for 20 min at a rate of 1 ml min−1 allowed for proper 
chromatographic separation. External AFM1 standards were prepared weekly and injected 
following every five injections of samples. The LOD for this method was 12 pg ml−1 of 
urine for AFM1. Random samples were aliquoted for additional verification using a Waters 
Acquity H-Class UPLC-MS/MS. Separation was achieved using a 2.1 × 50 mm Acquity 
UPLC BEH C18 column with a particle size of 1.7 μm. Isocratic separation was achieved 
with 70% water buffered with 1% formic acid and 30% ACN buffered with 1% formic acid. 
Samples (10 μl) were injected onto the column and the elution rate was 0.325 ml min−1. The 
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column effluent was directly coupled to the MS, which was operated in the positive 
electrospray ionisation mode. MS/MS conditions were optimised for AFM1 and based on 
Warth et al. (2012). The precursor ion was set to 329.00 Da and the two product ions were 
273.00 Da (quantifying ion) and 259.1 Da (qualifying ion). Urinary AFM1 concentrations 
were expressed as pg mg−1 creatinine to correct for variations in urine dilution among 
samples. Creatinine concentrations were measured at Baylor Scott & White Hospital 
(Temple, TX, USA).
Determination of serum AFB1-lysine adduct level
Previous measurements of aflatoxin exposure in Kenya have been based on the serum 
aflatoxin B1-lysine adduct from serum albumin (AFB1-lys), a biomarker for long-term 
aflatoxin exposure. This allowed us to compare aflatoxin exposure with levels seen during 
previous aflatoxicosis outbreaks. The CDC's National Center for Environmental Health 
Division of Laboratory Sciences analysed serum specimens for AFB1-lys adduct, which 
consisted of two measurements: (1) analysis AFB1-lys by LC-MS/MS (McCoy et al. 2005); 
and (2) albumin measurement. To allow the release of AFB1-lys from albumin, protein in 
serum specimens was digested in the presence of stable-iso-topically labelled internal 
standard (2H4-AFB1-lys) for at least 15 h at 37°C by use of a commercially available 
mixture of proteinases (Pronase™). AFB1-lys and 2H4-AFB1-lys were then extracted by use 
of mixed-mode anion exchange reversed-phase SPE. Each SPE eluate was evaporated, 
reconstituted in mobile phase and injected onto a reversed-phase C18 column. AFB1-lys was 
chromatographically separated from other compounds using gradient mobile phase. Both 
AFB1-lys and 2H4-AFB1-lys were detected with positive electrospray ionisation (ESI) in 
SRM mode using tandem quadrupole mass spectrometry (McCoy et al. 2005). Quantitation 
was based on peak area ratios interpolated against a seven-point aqueous linear calibration 
curve with 1/x weighting. The calibration range for serum AFB1-lys was 0.025–10 ng ml−1. 
There are no established critical call values for serum AFB1-lys concentrations, i.e., there 
are no defined concentration thresholds distinguishing a normal or acceptable serum AFB1-
lys concentration from one that would be considered abnormal or life threatening. The LOD 
for AFB1-lys was 0.02 ng ml−1. Serum albumin was analysed on the Hitachi Modular P 
clinical analyser using the Roche® colorimetric assay. The LOD for albumin was 0.2 g dl−1. 
Human serum albumin – and subsequently albumin-corrected serum AFB1-lys – has a half-
life of approximately 20 days. Thus, detection of AFB1-lys in this assay suggests a 
likelihood of exposure to aflatoxin within the previous 1–2 months.
Statistical methods
We used Epi Info™ 7 (CDC, Atlanta, GA, USA) for data entry and SAS Enterprise Guide 
version 4.3 (SAS Institute, Cary, NC, USA) for data analysis. We performed all statistical 
analyses blinded, and we considered p < 0.05 to be statistically significant.
We compared demographic variables by group using paired t- and chi-square tests. We 
compared the palatability by treatment using Wilcoxon rank-sum test, and compared serum 
AFB1-lys levels between days 0 and 20 using the Wilcoxon signed-rank test. We assessed 
intra-individual correlation in urinary AFM1 levels using a Spearman correlation coefficient.
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To assess efficacy, we first created an outcome variable for each participant. The outcome 
variable was the average of a participant's urinary AFM1 level during the 7 days of follow-up 
(i.e., days 2–8) for each treatment. Urinary aflatoxin levels below the LOD were substituted 
with the LOD divided by the square root of 2 before being averaged. These averages were 
then log-transformed. Thus, each participant had two summary outcome variables: log-
transformed average urinary AFM1 during treatment; and log-transformed average urinary 
AFM1 during placebo. We then fitted a general linear model with fixed effects for subject, 
treatment and period. We performed a modified intent-to-treat analysis, meaning that we 
performed an intent-to-treat analysis on all individuals who completed the study.
Results
Study population and demographics
In order to enrol the study population of 50 participants, a total of 68 potential participants 
were consented and assessed. Eighteen participants were not enrolled because they did not 
meet the inclusion criteria (Figure 1). Study retention for randomised participants was 98%. 
One (2%) male participant dropped out on day 3 after being randomised and completing two 
treatment sessions. Thus, we included 49 participants in the statistical analyses.
The majority of participants were female (n = 36, 72%) (Table 1). Participants ranged in age 
from 21 to 75 years (mean = 39 years). Participant sex, age, weight, height and amount of 
time living in the village did not differ by group. Participants consumed an average of 1.9 
maize-containing meals per day; this did not differ by treatment (placebo, 1.8 maize-
containing meals per day; ACCS100, 1.9 maize-containing meals per day).
Compliance
The majority of participants consumed all 21 sachets during both the ACCS100 (n = 45) and 
placebo (n = 44) treatment. The majority (n = 46) of participants always ingested the sachet 
with water; four individuals reported consuming a sachet without water (but with food) once 
during the study. There were 23 participants who consumed a sachet without food (but with 
water) between one and three times during the study.
Efficacy
Forty-nine participants contributed data to both arms of the study and thus were included in 
the efficacy analyses. Participants provided 784 (98%) of the potential 800 urine samples. 
Overall, 48% of samples contained detectable levels of urinary AFM1 (range = < LOD–1986 
pg mg−1 creatinine).
Baseline urinary AFM1 levels also did not vary statistically by treatment. There was no 
statistical correlation in urinary AFM1 aflatoxin levels when comparing baseline of arm 1 
with the baseline of arm 2, or when comparing day 1 of arm 1 with day 2 of arm 1.
Table 2 depicts geometric mean average urinary AFM1 levels during follow-up (days 2–8)by 
arm and group. Our general linear model found that geometric mean urinary AFM1 was 
lower during ACCS100 compared with placebo (β = –0.7093, 95% confidence limit = –1.14 
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to –0.28; p < 0.01), while controlling for subject and period. Once exponentiated to account 
for the log transformation, the results indicate that urinary AFM1 was approximately half 
during treatment compared with placebo (0.49, 95% confidence limit = 0.32–0.75).
Figure 2 illustrates daily urinary AFM1 levels by treatment. As indicated by the error bars, 
there was not a statistically significant difference between ACCS100 and placebo when 
looking at any individual day.
The average level of consumption of calcium montmorillonite clay was 3 g day−1. Previous 
research has demonstrated that 3 g day−1 of clay was the minimal effective dose that 
significantly decreased the AFM1 bio-marker (Wang et al. 2008). This dose of clay (3 g 
day−1) is equivalent to 0.25% w/w in the adult Ghanaian diet, based on an intake of 
approximately 1200 g day−1.
Analysis of serum AFB1-lys levels
Thirty-nine participants provided serum data at both time points and thus were included in 
this analysis (Figure 3). Serum aflatoxin median levels exhibited a statistically significant 
decrease from day 0 (n = 39; median = 9.3 pg mg−1 albumin) to day 20 (n = 39; median = 
6.4 pg mg−1 albumin; p < 0.01). The day 0–20 interval includes both the placebo and 
ACCS100 treatments, as well as the wash out.
Palatability
There was a statistically significant difference in smell by treatment, with participants on 
average rating the placebo as 0.25 Likert points better than ACCS100 (p < 0.05). While the 
placebo and treatment had slight difference in colour, there were no statistically significant 
differences in ratings of taste, aftertaste, appearance, colour or texture by treatment (Table 
3).
The majority of participants rated aftertaste (98%), texture (97%), appearance (99%), smell 
(99%), taste (99%) and colour (99%) as either okay, good or really good for both the 
placebo and ACCS100. No one reported appearance, colour and taste as bad for the placebo. 
However, ACCS100 received a ‘bad’ rating from one participant (2.2%) for appearance, one 
(2.2%) for colour, one (2.2%) for taste and one (2.2%) for texture. Two (4.2%) people rated 
the placebo texture as bad.
Acceptability
Forty-seven participants completed the end-of-study questionnaire. Most participants (96%) 
had heard of aflatoxin prior to the study, and most (91%) worried about becoming sick as a 
result of exposure to afla-toxin. Two-thirds of participants (67%) knew of someone who had 
become sick from aflatoxin exposure in the past, and 9% believed they themselves had 
become sick from aflatoxin exposure at some point.
Most participants (98%) did not have any concerns about ACCS100 and would be willing to 
take ACCS100 (98%) or give it to their children (98%) if they knew it would protect them 
from aflatoxicosis. The majority of participants (72%) reported that they would prefer to 
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take the clay in water as they had done during the study; the other commonly mentioned 
option was taking the clay plain (i.e., licking it; 13%). Participants would be willing to take 
the clay for at least 2 weeks (40%) or as long as recommended (38%). Similarly, participants 
would be willing to let their children take the clay for at least 2 weeks (36%) or as long as 
recommended (47%).
Adverse events
Approximately one-quarter of participants reported at least one adverse event when taking 
placebo (n = 12, 26%) or ACCS100 (n = 14, 28%). The most commonly reported adverse 
events reported while on placebo were nausea (14%) and abdominal discomfort (8%); for 
ACCS100, they were abdominal discomfort (14%) and increased appetite (8%) (Table 4). 
Other side effects reported at least once were diarrhoea (reported once, while on ACCS100), 
and dizziness with headache (reported once, while on ACCS100). These percentages were 
calculated by dividing the number of times an adverse event was reported by the total 
potential number of times when it could have been reported. There were no statistically 
significant differences in the reporting of adverse events by treatment.
No adverse events were graded as severe. Approximately one-third of side effects on 
ACCS100 (n = 6, 35%) and placebo (n = 7, 39%) were rated as moderate.
Discussion
We found no relationship between self-reported adverse events and treatment type. Two of 
the most commonly reported side effects in our study were abdominal discomfort and 
nausea, and both have been reported in previous studies. One difference in the present study 
is that a small number of participants reported increased appetite. It is possible participants 
may have paid more attention to their level of hunger because we performed our study 
during a time of relatively high food insecurity.
Another difference between our study and earlier work is the delivery mechanism. 
Previously, ACCS100 had been delivered in food, or as a pill. This is the first study to show 
that clay can be palatable and acceptable when mixed with water. This is significant because 
clay delivery in water might be more rapid and feasible during an outbreak period compared 
with delivery in food or capsules.
We found ACCS100 to be effective in reducing aflatoxin bioavailability. Participants in both 
groups had lower urinary AFM1 levels while taking ACCS100 compared with placebo. 
During a similar crossover study in Ghana, participants also exhibited lower urinary AFM1 
levels while taking clay compared with placebo, though the effect was statistically 
significant in only one group (Mitchell et al. 2013). Baseline urinary AFM1 levels were 
approximately 80 times higher during the crossover trial in Ghana than what we found in 
Kenya, suggesting that participants in our study had lower exposure to aflatoxin. 
Importantly, the dose of ACCS100 (i.e., 0.25% w/w) represents a minimal effective 
concentration based on extensive earlier work in animals and has been kept at this level as a 
safety measure during human trials. Studies have shown that the clay is tolerable in animals 
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as high as 2.0% w/w. It is possible that a higher dose of clay will be more efficacious during 
an outbreak or emergency. Further work is warranted to investigate the dosimetry of 
ACCS100.
Median AFB1-lys levels in our study participants (9.3 pg mg−1 albumin on day 0 and 6.4 pg 
mg−1 albumin on day 20) were similar to median levels reported during a previous study that 
measured AFB1-lys levels in Kenya's Eastern Province during a non-outbreak period (7.9 pg 
mg−1 albumin) (Yard et al. 2013). As expected, AFB1-lys levels were much lower during 
this study compared with levels reported among patients with presumed acute aflatoxin 
toxicity during aflatoxicosis outbreaks in Kenya in 2004, 2005 and 2010, when geometric 
mean levels ranged from 120 to 1200 pg mg−1 albumin (Azziz-Baumgartner et al. 2005).
The decrease in serum aflatoxin from 9.3 pg mg−1 albumin on day 0 and 6.4 pg mg−1 
albumin on day 20 may be the result of treatment with ACCS100 or might reflect a decrease 
in dietary exposure to aflatoxin. Longer-term studies using this biomarker are warranted.
There are multiple strategies to prevent aflatoxin contamination and exposure. A variety of 
long-term solutions include reducing aflatoxin contamination in maize through improved 
harvesting, drying and storage (Turner et al. 2005); planting resistant cultivars (Hell et al. 
2008), bio-control (Cotty et al. 2007; Yin et al. 2008), and/or a gradual shift to a more 
diverse diet (Wu et al. 2014). However, even with the implementation of these strategies, it is 
still difficult to eliminate aflatoxins completely. Thus, short-term interventions are needed in 
Kenya to respond to afla-toxin outbreaks.
A number of further research questions need to be answered before ACCS100 could be 
incorporated into an outbreak-response strategy. First, we do not know if ACCS100 will be 
efficacious in the higher exposure levels like those seen during outbreaks. Second, more 
work is needed to test the safety, efficacy, acceptability and palatability among vulnerable 
populations, such as children, individuals in poor health and pregnant women, who are often 
most at risk for aflatoxicosis. Third, though we have seen evidence of ACCS100 reducing 
aflatoxin bioavailability, we do not know if that will correlate to improved health outcomes. 
Fourth, we do not know if the reduction in bioavail-ability is fast enough to prevent toxicity.
ACCS100 has the potential to be incorporated in outbreak-response activities to prevent 
poisoning and protect people during high-risk periods. This pilot study was designed to 
confirm the efficacy, acceptability and palatability of ACCS100 in a high-risk population in 
Kenya.
It had a few limitations, though. Compliance with the study protocol was measured via self-
reported data, which may have biased results towards the null. However, this appeared not to 
have been an issue, as we still observed a statistically significant decrease of AFM1 levels 
when participants were on ACCS100 compared with placebo. There was no untreated or 
placebo-only group, so we do not know if the results were due to a trend in exposure or 
clearance, or if the treatment was effective.
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This study was conducted in a region of Kenya that had a very high awareness of aflatoxin 
due to prior outbreaks. It is possible that other regions of Kenya may not have been as 
accepting of ACCS100 or found it as palatable. However, this is the region where ACCS100 
could be used in future due to its history of high exposure and previous outbreaks.
Although many questions remain, the results from this pilot study are encouraging. They 
suggest that ACCS100 would be acceptable in Kenya's Eastern Province. The decrease in 
urinary AFM1 biomarkers during ACCS100 treatment should be further explored to 
determine if ACCS100 could be a potential treatment to protect individuals at risk for 
aflatoxin poisoning.
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Overall design and participants flow for the ACCS100 crossover study.
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(colour online) Geometric mean and 95% confidence intervals of urinary aflatoxin AFM1 
(pg mg−1 creatinine) by day.
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Box whiskers/connected dot plot of AFB1-lys for 39 participants on days 0 and 20 of follow-
up. The day 0–20 interval includes both the placebo and ACCS100 treatments, as well as the 
wash out.
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Table 1
Study population demographics, by group.
Demographic Overall Group I (placebo then ACCS100) Group II (ACCS100 then placebo)
Sex (%)
 n 50 25 25
 Female 36 (72%) 17 (68%) 19 (76%)
 Male 14 (28%) 8 (32%) 6 (24%)
Age (in years)
 n 48 25 23
 Range 21–75 21–68 21–75
 Mean 39.3 40.6 37.9
 SD 12.3 12.8 11.9
Weight (kg)
 n 47 23 24
 Range 40.0–94.5 41.5–88.0 40.0–94.5
 Mean 58.4 61.8 55.1
 SD 7.8 12.7 10.8
Height (cm)
 n 47 23 24
 Range 142.2– 185.4 151.0–185.4 142.2–173.5
 Mean 161.6 163.0 160.2
 SD 7.8 8.1 7.5
Duration of stay in the village (years)
 n 50 25 25
 Range 1–55 4.0–55.0 1.0–51.0
 Mean 20.0 22.5 17.4
 SD 15.2 16.0 14.3
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Table 2
Urinary aflatoxin AFM1 concentrations (pg mg−1 creatinine) during follow-up (days 2–8), by group and arm.








AFM1:GM (95% CI) 10 (4.0–26) 18 (7.2–44)
Note: The general linear model compared log average AFM1 levels during days 2–8 between ACCS100 and placebo: β (95% confidence limit) = – 
1.14 to –0.28; p < 0.01.
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Table 3
Palatabilitya ratings reported by treatment.









Ratings reflect a five-point Likert scale (1 = really bad, 2 = bad, 3 = okay, 4 = good, 5 = really good).
b
p < 0.05 comparing ACCS100 with placebo using a Wilcoxon rank-sum test.
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Table 4
Adverse events reported, by treatment.
Side effect Placebo
(participants: n = 50)
(possible times: n = 350)a
ACCS100
(participants: n = 49)
(possible times: n = 343)
Abdominal discomfort
Number of participants reporting 4 (8%) 7 (14%)
Number of times reported 5 (1%) 9 (3%)
Nausea
Number of participants reporting 7 (14%) 2 (4%)
Number of times reported 8 (2%) 4 (1%)
Increased appetite
Number of participants reporting 3 (6%) 4 (8%)
Number of times reported 6 (2%) 4 (1%)
Note:
a
Possible times was calculated by multiplying the number of participants by the number of days of treatment.
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